Tree News

GlobeNewswire · 2026-10-27 10:00 UTC

Aclaris Therapeutics Announces Positive Phase 1b Proof-of-Concept Primary Analysis Results for its Anti-TSLP/IL-4Rα Bispecific ATI-052 in Atopic Dermatitis (AD) and Asthma - GNW

Loading the story on Tree News…